21世纪经济报道记者韩利明上海报道 "2023年是医疗AI大模型元年，企业纷纷跑马圈地，推动大模型应用落地。"这是业内对2023年医疗AI大 模型的界定。2024年底，国家卫生健康委牵头制定了《卫生健康行业人工智能应用场景参考指引》，列 出了AI在医疗领域创新应用的84个领域，为AI在医疗行业的进一步拓展提供了明确方向。 各地也在积极响应。上海市发布了《上海市发展医学人工智能工作方案(2025-2027年)》，从政策层面为 医疗AI的发展提供保障与支持；四川省则在2025年政府工作报告中提及，"发展互联网医院、远程诊疗 和'AI+医疗'，促进优质医疗资源更好下沉共享"。 2025年以来，随着DeepSeek等国产大模型取得突破，医疗大模型及AI应用热潮再度高涨。众多三甲医 院、专科医院等官宣已完成DeepSeek的本地化部署，其他医疗服务机构也加速跟进。这背后，是我国 医疗资源长期失衡的现状，医疗领域亟需AI支持。 上海交通大学医学院附属仁济医院(以下简称"仁济医院")泌尿科主任潘家骅向21世纪经济报道等解 释，"我国95%的医疗机构为基层医院，却出现患者扎堆少量三级医院的现象，导致三甲医院人满为 患，医生超 ...

Core Insights - The article discusses the recent seed round financing of Meiyin Intelligent Technology Co., Ltd., which raised tens of millions of yuan to develop AI-driven disease risk prediction and health management solutions [4][5]. Company Overview - Meiyin Intelligent focuses on utilizing AI technology for disease risk prediction and health management, with its core product being a disease risk prediction platform based on its self-developed large model [4]. - The company was incubated at Peking University Science Park and aims to provide AI-driven insurance and disease risk management solutions for individuals at risk of severe and chronic diseases [4]. Technology and Innovation - The company's self-developed DP-LLM model supports multimodal medical data and quantifies individual future disease risks, covering hundreds of diseases and thousands of risk factors [4]. - The CEO, Guo Xiaoyu, emphasizes the shift from traditional medical AI to generative models that can predict future health conditions based on historical health data [5]. - The model allows for more precise segmentation of insurance products, enabling coverage for individuals with early disease risks who were previously excluded [5]. Market Strategy - Meiyin Intelligent is currently focusing on commercial insurance as a payment channel, collaborating with government departments and large insurance companies to enhance health insurance products [6]. - The company plans to monetize through B2B technology service fees, C2C subscriptions, and risk-sharing models, aiming to reach more end-users [6]. Team and Expertise - The founding team possesses a strong academic background and practical experience in the medical AI field, with Guo Xiaoyu having over 10 years of experience in R&D and commercialization [7]. - The team includes experts from prestigious institutions and companies, enhancing the company's capabilities in AI model development and deployment [7]. Investor Perspectives - Investors highlight the team's combination of academic excellence and practical experience, noting the significant advantages of the disease prediction model in lightweight deployment and multimodal integration [8]. - The company's approach aligns well with the development plans for the digital health industry in Hangzhou, focusing on efficient iterations of health insurance products [8].

Summary of the Conference Call for Chuangyue Huikang Company Overview - **Company**: Chuangyue Huikang - **Year**: 2024 - **Revenue**: 1.422 billion CNY - **Net Profit**: -192 million CNY - **Industry Contribution**: Medical industry accounted for 93.25% of revenue Key Financial Insights - Revenue decreased by 11.96% year-on-year, with a significant drop in net profit from 1.73 billion CNY to -192 million CNY [4][2] - Medical revenue from Corcept declined from 844 million CNY to 675 million CNY [4][2] - Public health sector orders dropped from 40% to approximately 30% of total orders due to insufficient fiscal funding [4][2] - Increased bad debt provisions by 70-80 million CNY negatively impacted net profit [4][2] Product and Project Developments - HIS system project contracts increased by 41% year-on-year, totaling 31 contracts [5][2] - Transition between old and new products extended delivery cycles, affecting product acceptance and payment timelines [5][2] - Plans to enhance the promotion of HealthFace products, with expectations for improved delivery cycles by the second half of the year [5][6] Collaborations and Partnerships - Collaboration with Philips is progressing well, although the promotion of Feiyuekang products did not meet expectations [7][2] - Future products will integrate into HealthSpace for easier client promotion [7][2] AI and Technology Advancements - Launched CDSS and other AI products, with over 20 clients in pilot programs and ten medical institutions completing applications post-Spring Festival [8][9] - Significant demand for AI solutions in the medical sector, with over ten hospitals having clear project implementations [10][2] - Collaboration with Zhejiang University to develop a medical large model, focusing on vertical industry knowledge integration and AR capabilities [11][2] Market Trends and Demand - Increased demand for AI in medical institutions, particularly for system upgrades and improvements [3][19] - Hospitals are preparing for new standards requiring AI functionalities, impacting existing module improvements [20][21] - The need for AI in hospitals is expected to influence project profit margins due to budget constraints [24][2] Future Directions - Plans to deepen AI integration into medical information systems over the next 5 to 10 years, focusing on algorithm development and data platform construction [14][2] - Emphasis on AR technology as a core component of medical processes rather than an auxiliary system [15][2] - Continued focus on enhancing diagnostic accuracy in grassroots medical settings through AI [28][2] Challenges and Strategic Responses - High costs associated with AI R&D and talent acquisition pose challenges, but partnerships with universities help mitigate these costs [22][2] - The company is adapting to budget constraints in hospitals, which may limit AI project funding [35][2] - The competitive landscape is shifting, with larger firms gaining market share while smaller companies struggle to survive [46][2] Conclusion Chuangyue Huikang is navigating a challenging financial landscape while making strides in AI and technology integration within the medical sector. The company is focusing on strategic partnerships, product development, and adapting to market demands to enhance its competitive position in the evolving healthcare landscape.

Group 1 - The launch of the "Yuan Zhi" medical model by United Imaging on April 9, which includes over 10 medical AI applications covering various scenarios such as imaging diagnosis and patient services [1] - The "Yuan Zhi" medical imaging model is trained on tens of millions of medical imaging data and hundreds of thousands of finely annotated data, achieving over 95% accuracy in key tasks like complex lesion diagnosis and organ segmentation [1] - The challenges of data privacy, ethical review, and building trust between doctors and patients remain significant hurdles for the practical implementation of medical AI [1] Group 2 - The unveiling of the Guangdong Provincial Transportation Industry Computing Power Center on April 9, which is a key infrastructure for the digital transformation of the transportation sector in Guangdong [2] - The center is built according to national A-level data center standards, with a plan for 638 standard cabinets, and the initial phase has completed 324 cabinets to meet diverse computing needs [2] - The investment in high-standard resources is expected to enhance road network management efficiency and data-driven decision-making capabilities in the transportation industry [2] Group 3 - The upcoming AI training course for provincial officials in Zhejiang, featuring Wang Xingxing, the founder and CEO of Yushu Technology, who will discuss the current state and development trends of the robotics industry [3] - This initiative reflects the local government's emphasis on the strategic importance of the robotics industry and aims to facilitate better alignment between policy and market resources [3] - Continuous updates to the knowledge system in training programs are necessary to prevent disconnection between theoretical understanding and industry practice [3]

Group 1 - The 91st China International Medical Equipment Fair (CMEF) opened in Shanghai, showcasing nearly 5,000 brand enterprises with a theme of "Innovative Technology Leading the Future" [1] - Mindray Medical presented over 40 innovative products, including the world's first clinical application of a critical care large model, the Qiyuan model, which enhances clinical capabilities [1][3] - Mindray's AI solutions, "Digital Laboratory" and "Ruiying Ecosystem," focus on integrating "Equipment + IT + AI" to empower medical services across various clinical scenarios [5] Group 2 - The Qiyuan critical care large model has been implemented in several top medical institutions in China, marking a significant step in the application of general models in specialized medical fields [5] - Mindray's "Digital Laboratory" achieves breakthroughs in "Digital Testing," "Digital Operations," and "Digital Development" through deep integration of technology [5] - The "Ruiying Ecosystem" provides comprehensive AI solutions across obstetrics, radiology, cardiovascular, and point-of-care testing, enhancing the medical imaging digital ecosystem [5] Group 3 - Mindray has emphasized global expansion, adapting to challenges in international markets, particularly in response to recent U.S. tariff policies [7] - Despite tariffs since 2018, Mindray's U.S. business has seen a compound annual growth rate of 10% from 2018 to 2023, with U.S. sales accounting for a significant portion of total revenue [8] - The company plans to strengthen its position in the North American high-end market with products like the Resona A20, while also focusing on growth in developing countries, which account for two-thirds of overseas revenue [8]

Core Viewpoint - Ant Group, in collaboration with Huawei and Alibaba Cloud, has launched a comprehensive AI solution for hospitals, marking a significant step in the application of AI in the medical field, integrating AI capabilities across institutions, doctors, and patients [1][4][15] Group 1: AI Model and Medical Service Upgrade - The introduction of large models is driving an upgrade in medical services, with significant breakthroughs in technology lowering the barriers for AI in healthcare [2][3] - Major players like Huawei, Tencent, and Ant Group are entering the medical AI space, indicating a competitive landscape for AI applications in healthcare [4][15] Group 2: Ant Group's Unique Approach - Ant Group has a long history of involvement in digital healthcare, having established a strong foundation over 11 years, which positions it well for the integration of AI in medical services [7][10] - The company has developed a "three-in-one" strategy that integrates AI applications for institutions, doctors, and patients, enhancing the overall healthcare ecosystem [5][6][15] Group 3: AI Product Offerings - Ant Group has launched various AI tools for different stakeholders: a full-stack AI solution for hospitals, AI assistant tools for doctors, and an "AI Health Manager" for patients [5][6][14] - The AI Health Manager has already served nearly 30 million users across over 1,000 medical institutions in Zhejiang Province [14] Group 4: Future Prospects and Industry Impact - The integration of AI in healthcare is expected to significantly improve resource utilization and reduce costs, with predictions indicating a potential saving of over $1.2 trillion globally by 2030 [15] - Ant Group's model of open technology and collaboration with nearly 100 partners is seen as a practical example for the scalable implementation of medical AI [15]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [2][11]. Core Insights - New technology platforms are increasingly favored by multinational corporations (MNCs), leading to earlier collaboration opportunities. A notable example is the global strategic partnership between Heptares Therapeutics and AstraZeneca, which includes a $105 million equity investment [3]. - The weight loss market is seeing multiple business developments (BD) materialize, with significant sales growth reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated approximately $27.94 billion in sales, while Eli Lilly's tirzepatide saw a 124% year-on-year increase in sales to $11.54 billion [5]. - Progress in universal CAR-T and solid tumor cell therapies is ongoing, with global CAR-T sales projected at approximately $4.53 billion in 2024. Chinese companies are also participating in this market, with three domestic CAR-T products approved for sale [6]. - The CRO (Contract Research Organization) environment may experience changes, with potential supply flexibility due to the easing of U.S. bioterrorism law concerns. This could enhance the competitiveness of Chinese CROs [7]. - The active pharmaceutical ingredient (API) sector is exploring new applications, particularly in the nicotine tobacco production sector, leveraging synthetic biology technologies [8]. - Major hospitals are launching specialized AI models, indicating a rising trend in the integration of AI in healthcare, with collaborations between tech companies and healthcare providers [10]. Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.88 percentage points over the past week, ranking 20th among 31 primary industry indices [20]. 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's index has a current PE (TTM) of 30.95, which is below the five-year historical average of 32.98 [36]. 3. Recent Research Achievements - The research team has published several in-depth reports on various pharmaceutical sectors, highlighting trends such as the growth of blood products and the impact of policy support on inhalation drug industries [40]. 4. Important Industry Policies and News - Recent policy changes include the National Medical Products Administration's (NMPA) decision to abolish certain medical device standards to optimize the regulatory framework [42]. - Significant industry news includes the approval of several new drug applications and clinical trials by the NMPA, indicating a robust pipeline for pharmaceutical innovation [44][46].

即便是前公募冠军基金经理，也会因为谨慎而选择借道指数基金产品去布局。 3月20日晚间，募集期只有7个工作日的易方达恒生港股通创新药基金，披露的上市交易公告书显示，前公募冠军张小仁创立的私募基金，已成为该港股创新 药指数基金的前十大份额持有人之一。张小仁投资偏好科技赛道，曾在2014年基金业绩排名中获得公募冠军，他此前也曾向证券时报·券商中国记者强调，基 金经理要做好投资业绩，就要面对自己的能力圈、在选股时要做减法并承认自己并非任何赛道都懂的全能手。 值得一提的是，创立私募的前公募冠军基金经理借助公募指数产品，布局港股创新药赛道的现象，凸显出当前港股市场尤其是连跌三年的创新药行业，已几 乎成为港股市场最锋利的矛之一，多位医药基金经理判断年内港股创新药赛道是最大投资主线之一，股价驱动因素往往是新药临床、新药获批与上市等进展 性公告和消息以及稀缺性的爆款药。 前公募冠军借"基"上车 基金经理对自己不太熟悉，但预期赛道趋势升温显著的行业，正通过行业指数基金进行覆盖。 3月20日晚，易方达基金发布的易方达恒生港股通创新药基金上市交易书显示，部分公转私的基金经理正通过指数基金南下港股创新药赛道，在易方达恒生港 股通创新药 ...

Group 1 - Company plans to invest 70 million yuan to acquire 0.70% equity in Shanghai United Imaging Intelligent Medical Technology Co., Ltd. (United Imaging Intelligent) [1] - After the investment, the total equity held in United Imaging Intelligent will be 0.9849% [1] - The controlling shareholder of the company, United Imaging Medical Group Co., Ltd., and Shanghai Lianhe Investment Co., Ltd. will also participate in the investment, acquiring 2.0000% and 1.7901% equity respectively [1] Group 2 - United Imaging Intelligent is a medical AI company providing integrated intelligent solutions across multiple scenarios and diseases, playing a crucial role in the AI strategy of United Imaging Group [2] - The company has launched over 100 medical AI products, excelling in clinical applications such as disease screening, early diagnosis, and treatment planning [2] - The investment aims to enhance the company's product offerings with intelligent support, optimizing the use of medical equipment and meeting the demand for efficient and precise healthcare [2]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1]. Core Insights - The global new drug business development (BD) remains robust, with approximately 31% of innovative drug candidates introduced by multinational pharmaceutical companies in 2024 coming from China. In the first two months of 2025, there have already been 16 Chinese innovative drug BD projects, expanding from oncology to autoimmune diseases [3]. - The weight loss market is seeing multiple BD agreements, with significant sales figures reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated sales of approximately $27.94 billion in 2024, while Eli Lilly's Mounjaro saw a 124% year-on-year increase in sales to $11.54 billion [5]. - CAR-T cell therapy continues to progress, with global sales expected to reach approximately $4.53 billion in 2024. Chinese companies are also participating in the global CAR-T sales, indicating their technological capabilities [6]. - The gene sequencing industry is accelerating its domestic production capabilities following export restrictions on Illumina's sequencing instruments. Domestic alternatives are rapidly emerging, with several companies receiving regulatory approvals for their sequencing devices [7]. - AI in healthcare is advancing, with various AI models being developed for specific medical fields. Collaborations between tech companies and healthcare providers are enhancing the integration of AI into traditional medical practices [9]. Summary by Sections Industry Trends - The pharmaceutical industry outperformed the CSI 300 index by 0.18 percentage points in the past week, with a weekly increase of 1.77% [23]. - Over the past month, the pharmaceutical sector also outperformed the CSI 300 index by 0.22 percentage points, with a monthly increase of 1.94% [27]. Subsector Performance - The pharmaceutical commercial sector saw the highest weekly increase of 6.44%, while the medical device sector had the lowest at 1.09% [30]. - Over the past year, the chemical pharmaceutical sector had the highest increase of 6.49%, while the biological products sector experienced a decline of 17.62% [37]. Company Recommendations - The report recommends focusing on companies involved in weight loss and NASH, such as Zhongsheng Pharmaceutical, and highlights the potential of companies like Geli Pharmaceutical and Lianbang Pharmaceutical [12]. - Companies engaged in CAR-T technology, such as Kexin Pharmaceutical, are also recommended as they approach market entry [12]. - The report emphasizes the importance of AI integration in medical devices, recommending companies like Anbiping and RunDa Medical for their competitive advantages [12]. Recent Developments - The report notes significant recent financing and regulatory approvals for various companies, indicating a dynamic and evolving market landscape [54][55].